Earnings are out
Daxor (DXR)
Supplies blood-volume diagnostic kits and BVA analyzers.
$10.10
At close−0.80 (−7.34%)
In millions of USD, except per-share figures
| In millions | Q4 FY20Dec 2020 | Q2 FY21Jun 2021 | Q4 FY21Dec 2021 | Q2 FY22Jun 2022 | Q4 FY22Dec 2022 | Q2 FY23Jun 2023 | Q4 FY23Dec 2023 | Q2 FY24Jun 2024 | Q4 FY24Dec 2024 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 2 | 2 | 6 | 2 | 7 | 3 | 1 | 0 | 1 | 0 | −10 | 3 | |
| 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| General & administrative | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −10 | 3 |
| Operating income | 0 | 0 | 0 | 0 | −1 | 0 | 3 | 0 | 2 | 0 | 10 | −3 |
| 2 | −1 | 7 | −2 | 8 | −3 | 0 | −3 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | 2 | −2 | 6 | −2 | 7 | −3 | 3 | −3 | 2 | 0 | 10 | −3 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −2 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 2 | −2 | 6 | −2 | 7 | −3 | 3 | −2 | 2 | 0 | 10 | −3 |
| Net income | 2 | −2 | 6 | −2 | 7 | −3 | 3 | −2 | 2 | 0 | 10 | −3 |
| EPS, basic | $0.23 | −$0.19 | $0.78 | −$0.22 | $0.81 | −$0.46 | $0.72 | −$0.34 | $0.44 | −$0.07 | $1.89 | −$0.66 |
| EPS, diluted | $0.23 | −$0.19 | $0.78 | −$0.22 | $0.81 | −$0.46 | $0.72 | −$0.34 | $0.44 | −$0.07 | $1.89 | −$0.66 |
| Weighted average shares, basic | 8 | 8 | 8 | 8 | 9 | 7 | 5 | 5 | 5 | 5 | 5 | 5 |
| Weighted average shares, diluted | 8 | 8 | 8 | 8 | 9 | 7 | 5 | 5 | 5 | 5 | 5 | 5 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 3 | 0 | 10 | −3 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| EBIT | 0 | 0 | 0 | 0 | −1 | 0 | 0 | −2 | 2 | 0 | 10 | −3 |
